Brought to you by 
Covagen begins Series B round with CHF42mm; could get CHF14mm more
24 Feb 2014
Executive Summary
Covagen AG (therapeutic antibodies for inflammatory diseases and cancer) announced a CHF42mm ($47mm) tranched Series B round, which the company says is one of the largest private rounds for preclinical-stage European biotech. New investor GIMV led (with a CHF8.3mm), and was joined by other new buyer Ascent Biomedical Ventures and returning backers Novartis Venture Funds, Edmond de Rothschild Investment Partners, Seroba Kernel Life Sciences, Ventech, and MP Healthcare Venture Management. GIMV and Ascent have joined Covagen's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Covagen begins Series B round with CHF42mm; could get CHF14mm more
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice